XML 46 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2019
Nov. 30, 2017
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Jan. 31, 2016
May 13, 2010
Shareholders' Equity (Textual) [Abstract]                        
Repurchase outstanding common shares                     $ 10,000,000 $ 10,000,000
Repurchase of shares, value     $ (1,361,689) $ (531,746) $ (703,790) $ (401,747) $ (784,505) $ (1,195,225)        
Number of shares sold (in shares)           117,729            
Shelf Registration, sale of corporate securities (up to)   $ 100,000,000                    
Proceeds from sales of common stock, net of offering costs                 $ 0 $ 200,909    
Contribution of cash $ 300,000                      
Conversion of intercompany loans payable 700,000                      
WinHealth                        
Shareholders' Equity (Textual) [Abstract]                        
Investment through purchase of shares of CET Stock 1,000,000                      
Gloria Pharmaceuticals                        
Shareholders' Equity (Textual) [Abstract]                        
Cash payments for return of shares $ 800,000                      
Restricted Stock                        
Shareholders' Equity (Textual) [Abstract]                        
Restricted stock granted in period, shares                 225,869 233,330    
Director | Restricted Stock                        
Shareholders' Equity (Textual) [Abstract]                        
Restricted stock awards, vesting period                 1 year      
Common stock                        
Shareholders' Equity (Textual) [Abstract]                        
Repurchase of shares (in shares)     246,242 84,447 121,466 66,278 127,291 172,079 452,155 365,648    
Repurchase of shares, value     $ (1,361,689) $ (531,746) $ (703,790) $ (401,747) $ (784,505) $ (1,195,225) $ (2,600,000) $ (2,400,000)    
Common stock issued                   30,704    
Proceeds from the sale of common stock, net of offering costs (in shares)               30,704